On October 24, 2018 the Federal Circuit ruled in favor of Finnegan client Biogen, affirming a Patent Trial and Appeal Board decision that determined Forward Pharma AS was not entitled to a patent on a method for treating multiple sclerosis used in Biogen’s multi-billion dollar drug Tecfidera. Forward argued that it sought patent claims on the same method in the same year Biogen was issued the patent. The Federal Circuit disagreed, stating that Forward’s application did not actually disclose the claimed treatment. As a result of the decision, Biogen does not have to pay royalties on Tecfidera to Forward.
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.